What is Hemato Oncology Testing Market?
Hemato oncology testing includes the analysis of blood disorders in the field of medicine such as iron deficiency anemia, hemophilia, sickle cell disease, leukemia, and lymphomas as well as cancers of other organs. Technological advancements with precise use of the information will make the entire hemato oncology testing reliable and effective. The part of hematological malignancies is helpful in the diagnosis and treatment of cancers of the bone marrow, blood and lymph nodes. Increasing cases of blood cancers, growing awareness among the population, and an increase in medical testing facilities are anticipated to propel the growth of the market during the forecast period.
The market study is being classified by Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms and Others), by Application (Assay Kits and Reagents and Services) and major geographies with country level break-up.
CORE Diagnostics (India), Tata Memorial Centre (India), Max Healthcare (India), Medanta The Medicity (India), Dr. Lal PathLabs (India), Narayana Hrudayalaya Ltd. (India), MedGenome (India), Oncquest.net (India), HealthCare Global Enterprises Ltd. (India) and The Mission Hospital (India) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (United States), Thermo Fisher Scientific, Inc. (United States), Adaptive Biotechnologies (United States), Invivoscribe, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), QIAGEN N.V. (Germany), Illumina, Inc. (United States), MolecularMD (Ireland), Asuragen, Inc. (United States) and ArcherDx, Inc. (United States).
Research Analyst at AMA predicts that India Players will contribute to the maximum growth of Global Hemato Oncology Testing market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Hemato Oncology Testing market by Type, Application and Region.
On the basis of geography, the market of Hemato Oncology Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Inclination of People towards an Early Detection of Serious Diseases, and Rise in Prevalence of Lymphoma & Myeloma Cancers
- Growing Awareness about the Advanced Treatment Therapies among Population
- Growing Focus on Personalized Medicine
- Rise in the Availability of Advanced Molecular Techniques for the Diagnosis of Hemato Oncology
- Complex Regulatory Frameworks
- Delay in the Approval of New Molecular Diagnostic Tests
- Proliferation of Sequencing Techniques Such As NGS Due To the Increasing Cost of Development
- Sequencing of the Human Genome Project in the Field Of Genomics
- Intellectual Property Rights Protection Issues
Market Leaders and some development strategies
In May 2018, Invivoscribe, Inc. has partnered with the American University of Beirut Medical Center (AUBMC) to create a new center of excellence facility in the Middle East.
In December 2019, Adaptive Biotechnologies collaborated with AbbVie for the use of Adaptive’s NGS based minimal residual disease testing in the drug trials of multiple myeloma.
Key Target AudienceHemato Oncology Testing Service Providers, Hospitals & Clinics, Diagnostics Centers, Healthcare Professionals, End-Use Industries and Others
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase